Bcr

Summary

Gene Symbol: Bcr
Description: BCR, RhoGEF and GTPase activating protein
Alias: ALL, BCR1, CML, D22S11, D22S662, PHL, breakpoint cluster region protein, BCR/FGFR1 chimera protein, FGFR1/BCR chimera protein, breakpoint cluster region, renal carcinoma antigen NY-REN-26
Species: human
Products:     Bcr

Top Publications

  1. Maru Y, Witte O. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 1991;67:459-68 pubmed
    Sequences encoded by the first exon of BCR that bind to the ABL SH2 domain are essential for the activation of the ABL tyrosine kinase and transforming potential of the chimeric BCR-ABL oncogene...
  2. Wu Y, Liu J, Arlinghaus R. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene. 1998;16:141-6 pubmed
    b>Bcr is a novel serine/threonine protein kinase that is believed to require two cysteine pairs for activity (Maru and Witte, Cell, 67, 459, 1991)...
  3. Zhao X, Ghaffari S, Lodish H, Malashkevich V, Kim P. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002;9:117-20 pubmed
    ..We determined the crystal structure of the N-terminal oligomerization domain of Bcr-Abl (residues 1-72 or Bcr1-72) and found a novel mode of oligomer formation...
  4. Liu Y, Song Y, Ma W, Zheng W, Yin H. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leuk Res. 2013;37:349-56 pubmed publisher
    Chronic myeloid leukemia (CML) is associated with overexpression of BCR-ABL1, a nonreceptor tyrosine kinase critical for malignant transformation...
  5. Hughes T, Saglio G, Branford S, Soverini S, Kim D, Muller M, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204-10 pubmed publisher
    ..with imatinib-resistant or imatinib-intolerant CML-CP, the occurrence and impact of baseline and newly detectable BCR-ABL mutations were assessed...
  6. Khorashad J, Kelley T, Szankasi P, Mason C, Soverini S, Adrian L, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013;121:489-98 pubmed publisher
    b>BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs)...
  7. Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 2011;25:463-72 pubmed publisher
    Despite the success of imatinib mesylate (IM) in the early chronic phase of chronic myeloid leukemia (CML), patients are resistant to IM and other kinase inhibitors in the later stages of CML...
  8. Zheng X, Güller S, Beissert T, Puccetti E, Ruthardt M. BCR and its mutants, the reciprocal t(9;22)-associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer. 2006;6:262 pubmed
    The reciprocal (9;22) translocation fuses the bcr (breakpoint cluster region) gene on chromosome 22 to the abl (Abelson-leukemia-virus) gene on chromosome 9...
  9. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann W, et al. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004;199:673-85 pubmed
    The BCR-ABL1 kinase expressed in acute lymphoblastic leukemia (ALL) drives malignant transformation of human pre-B cells...

More Information

Publications88

  1. Yi S, Groffen J, Heisterkamp N. Transglutaminase 2 regulates the GTPase-activating activity of Bcr. J Biol Chem. 2009;284:35645-51 pubmed publisher
    ..b>Bcr and the closely related Abr negatively regulate the small G-protein Rac: loss of their combined function in vivo ..
  2. Bueno M, Perez de Castro I, Gómez de Cedrón M, Santos J, Calin G, Cigudosa J, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496-506 pubmed publisher
    ..This 7 Mb region encodes about 12% of all genomic microRNAs, including miR-203...
  3. Hallek M, Danhauser Riedl S, Herbst R, Warmuth M, Winkler A, Kolb H, et al. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 1996;94:5-16 pubmed
    The chimaeric bcr/abl oncogene is detected in virtually all cases of chronic myelogenous leukaemia (CML)...
  4. Aichberger K, Mayerhofer M, Krauth M, Skvara H, Florian S, Sonneck K, et al. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood. 2005;105:3303-11 pubmed
    ..been implicated in the pathogenesis of chronic myeloid leukemia (CML), a hematopoietic neoplasm associated with the BCR/ABL oncogene. We have examined expression of MCL-1 in primary CML cells and BCR/ABL-transformed cell lines...
  5. Korus M, Mahon G, Cheng L, Whitehead I. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr. Oncogene. 2002;21:4601-12 pubmed
    The oncogenic fusion protein p210 Bcr-Abl is causally associated with virtually all cases of chronic myelogenous leukemia...
  6. Baxter E, Hochhaus A, Bolufer P, Reiter A, Fernandez J, Senent L, et al. The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 2002;11:1391-7 pubmed
    Chronic myeloid leukaemia (CML) is characterized by the presence of the BCR-ABL fusion gene, usually in association with the t(9;22)(q34;q11) translocation...
  7. Pendergast A, Muller A, Havlik M, Maru Y, Witte O. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161-71 pubmed
    b>BCR-ABL is a chimeric oncogene implicated in the pathogenesis of Philadelphia chromosome-positive human leukemias. BCR first exon sequences specifically activate the tyrosine kinase and transforming potential of BCR-ABL...
  8. Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee J, et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem. 2010;285:5085-96 pubmed publisher
    ..targeted drugs, best exemplified by the BCR-ABL inhibitor imatinib in treating chronic myelogenous leukemia (CML)...
  9. Fernandes M, Reddy M, Gonneville J, DeRoo S, Podar K, Griffin J, et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009;114:1813-9 pubmed publisher
    ..our data hint at a common pathway for DSB repair whereby BCR-ABL, Tel-ABL, Tel-PDGFR, FLT3-ITD, and Jak2V617F all increase mutagenic repair...
  10. Groffen J, Stephenson J, Heisterkamp N, de Klein A, Bartram C, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36:93-9 pubmed
    ..8 kb, for which we propose the term "breakpoint cluster region" (bcr). The two patients having no rearrangements within bcr lacked the Ph' chromosome...
  11. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci P, et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 1994;13:764-73 pubmed
    The cytosolic 185 and 210 kDa Bcr-Abl protein tyrosine kinases play important roles in the development of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL)...
  12. Liu J, Wu Y, Ma G, Lu D, Haataja L, Heisterkamp N, et al. Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol. 1996;16:998-1005 pubmed
    The first exon of the BCR gene encodes a new serine/threonine protein kinase. Abnormal fusion of the BCR and ABL genes, resulting from the formation of the Philadelphia chromosome (Ph), is the hallmark of Ph-positive leukemia...
  13. Slupianek A, Dasgupta Y, Ren S, Gurdek E, Donlin M, Nieborowska Skorska M, et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 2011;118:1062-8 pubmed publisher
    Chronic myeloid leukemia chronic phase (CML-CP) CD34(+) cells contain numerous DNA double-strand breaks whose unfaithful repair may contribute to chromosomal instability and disease progression to blast phase (CML-BP)...
  14. Tedeschi F, Cardozo M, Valentini R, Zalazar F. Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia. Leuk Lymphoma. 2010;51:892-6 pubmed publisher
    ..the co-expression of the bcr-abl and HoxA9 genes in the follow-up of patients with chronic myeloid leukemia (CML). In the present work we measured the HoxA9 and bcr-abl gene expression in sequential samples...
  15. Dierov J, Sanchez P, Burke B, Padilla Nash H, Putt M, Ried T, et al. BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold. Leukemia. 2009;23:279-86 pubmed publisher
    ..to long-term changes in chromosomes and whether the phenotype is found in primary chronic myelogeneous leukemia (CML) cells. We have addressed both these issues...
  16. Chu S, Li L, Singh H, Bhatia R. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia. Cancer Res. 2007;67:7045-53 pubmed
    Chronic myelogenous leukemia (CML) results from the transformation of a primitive hematopoietic cell by the BCR/ABL gene...
  17. Xie S, Lin H, Sun T, Arlinghaus R. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21:7137-46 pubmed
    ..previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation...
  18. Warsch W, Grundschober E, Berger A, Gille L, Cerny Reiterer S, Tigan A, et al. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget. 2012;3:1669-87 pubmed
    We recently reported that chronic myeloid leukaemia (CML) patients harbour high levels of STAT5 when they progress to advanced phases of disease. Advanced disease is characterized by an increased incidence of BCR-ABL1 mutations...
  19. Olabisi O, Mahon G, Kostenko E, Liu Z, Ozer H, Whitehead I. Bcr interacts with components of the endosomal sorting complex required for transport-I and is required for epidermal growth factor receptor turnover. Cancer Res. 2006;66:6250-7 pubmed
    Virtually all patients with chronic myelogenous leukemia (CML) express an aberrant protein (p210 Bcr-Abl) that contains NH2-terminal sequences from Bcr fused to COOH-terminal sequences from Abl...
  20. Cirmena G, Aliano S, Fugazza G, Bruzzone R, Garuti A, Bocciardi R, et al. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia. Cancer Genet Cytogenet. 2008;183:105-8 pubmed publisher
    We report the occurrence of a BCR-JAK2 fusion gene in a case of acute myeloid leukemia (AML) resulting from a t(9;22)(p24;q11) translocation as the sole cytogenetic abnormality...
  21. Ress A, Moelling K. Bcr interferes with beta-catenin-Tcf1 interaction. FEBS Lett. 2006;580:1227-30 pubmed
    ..We demonstrate that expressed Bcr is able to bind the transcription factor Tcf1 to disrupt the Tcf1/beta-catenin complex...
  22. Quintas Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009;113:1619-30 pubmed publisher
    ..CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene...
  23. Shah N, Kasap C, Weier C, Balbas M, Nicoll J, Bleickardt E, et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell. 2008;14:485-93 pubmed publisher
    The BCR-ABL inhibitor dasatinib achieves clinical remissions in chronic myeloid leukemia (CML) patients using a dosing schedule that achieves potent but transient BCR-ABL inhibition...
  24. Million R, Van Etten R. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 2000;96:664-70 pubmed
    ..from a balanced translocation between chromosomes 9 and 22 and is found in patients with chronic myeloid leukemia (CML) and in some patients with acute B-lymphoid leukemia...
  25. Li S, Couvillon A, Brasher B, Van Etten R. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. EMBO J. 2001;20:6793-804 pubmed
    Growth factor receptor-binding protein-2 (Grb2) plays a key role in signal transduction initiated by Bcr/Abl oncoproteins and growth factors, functioning as an adaptor protein through its Src homology 2 and 3 (SH2 and SH3) domains...
  26. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985;315:758-61 pubmed
    ..8-kb region, for which we have proposed the name 'breakpoint cluster region' (bcr)...
  27. Radziwill G, Erdmann R, Margelisch U, Moelling K. The Bcr kinase downregulates Ras signaling by phosphorylating AF-6 and binding to its PDZ domain. Mol Cell Biol. 2003;23:4663-72 pubmed
    The protein kinase Bcr is a negative regulator of cell proliferation and oncogenic transformation. We identified Bcr as a ligand for the PDZ domain of the cell junction and Ras-interacting protein AF-6...
  28. Osmonov D, Aksenov A, Trick D, Naumann C, Hamann M, Faddan A, et al. Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection. BMC Urol. 2016;16:56 pubmed publisher
    ..The indications for salvage ePLND were biochemical recurrence (BCR) of PCa and suspect findings on (11)C-choline PET/CT...
  29. Mes Masson A, McLaughlin J, Daley G, Paskind M, Witte O. Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1986;83:9768-72 pubmed
    ..The N-terminal sequence of the protein is derived from the BCR gene on chromosome 22...
  30. Vasko T, Kaifie A, Stope M, Kraus T, Ziegler P. Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions. Int J Mol Sci. 2017;18: pubmed publisher
    ..addition, TL is able to predict the response rate of tyrosine kinase inhibitor therapy in chronic myeloid leukemia (CML), indicates clinical outcomes in chronic lymphocytic leukemia (CLL), and can be used as screening tool for genetic ..
  31. Abdollah F, Sood A, Sammon J, Hsu L, Beyer B, Moschini M, et al. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients. Eur Urol. 2015;68:497-505 pubmed publisher
    ..To report on long-term biochemical recurrence (BCR)-free survival, clinical recurrence (CR)-free survival, and salvage therapy rates in these patients...
  32. Chissoe S, Bodenteich A, Wang Y, Wang Y, Burian D, Clifton S, et al. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics. 1995;27:67-82 pubmed
    The complete human BCR gene (152-141 nt) on chromosome 22 and greater than 80% of the human ABL gene (179-512 nt) on chromosome 9 have been sequenced from mapped cosmid and plasmid clones via a shotgun strategy...
  33. Byrgazov K, Lucini C, Berkowitsch B, Koenig M, Haas O, Hoermann G, et al. Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors. Oncotarget. 2016;7:78083-78094 pubmed publisher
    ..mutations in the ABL1 kinase domain are an important mechanism of resistance to tyrosine kinase inhibitors (TKI) in BCR-ABL1-positive and, as recently shown, BCR-ABL1-like leukemias...
  34. Moumen A, Dehbi H, Kottwitz D, El Amrani M, Bouchoutrouch N, El Hadi H, et al. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients. Genet Mol Res. 2015;14:1044-55 pubmed publisher
    Chronic myeloid leukemia (CML) is characterized by BCR-ABL translocation and an increased number and migration of immature myeloid cells into the peripheral blood...
  35. Ong W, Evans S, Spelman T, Kearns P, Murphy D, Millar J. Comparison of oncological and health-related quality of life outcomes between open and robot-assisted radical prostatectomy for localised prostate cancer - findings from the population-based Victorian Prostate Cancer Registry. BJU Int. 2016;118:563-9 pubmed publisher
    ..The oncological outcomes of interest were: positive surgical margin (PSM) and biochemical recurrence (BCR), defined as postoperative PSA level of >0.2 ng/mL...
  36. Márquez Mota C, Rodriguez Gaytan C, Adjibade P, Mazroui R, Galvez A, Granados O, et al. The mTORC1-Signaling Pathway and Hepatic Polyribosome Profile Are Enhanced after the Recovery of a Protein Restricted Diet by a Combination of Soy or Black Bean with Corn Protein. Nutrients. 2016;8: pubmed
    ..divided into eight groups and fed one of the following diets: 20% casein (C), soy (S), black bean (B), B + Corn (BCr), Pea (P), spirulina (Sp), sesame (Se) or Corn (Cr)...
  37. Uzonyi B, Mácsik Valent B, Lukácsi S, Kiss R, Török K, Kremlitzka M, et al. Functional studies of chronic lymphocytic leukemia B cells expressing β2-integrin type complement receptors CR3 and CR4. Immunol Lett. 2017;189:73-81 pubmed publisher
    ..The concomitant, suboptimal stimulus via the BCR and TLR9 exerted either a synergistic enhancing effect or resulted in inhibition of proliferation and IL-10 ..
  38. Moyo T, Wilson C, Moore D, Eischen C. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene. 2017;36:4653-4661 pubmed publisher
    ..Although genomic studies suggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, signaling pathways essential to Myc-mediated B-cell transformation have not been ..
  39. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics. 2012;22:198-205 pubmed publisher
    Despite the enormous success of imatinib in chronic myeloid leukemia (CML), therapy resistance has emerged in a significant proportion of patients, partly because of the overexpression of ABC efflux transporters.
  40. Wang H, Wang X, Li J, Jing H, Xia S, Liu F, et al. Comparison of palygorskite and struvite supported palygorskite derived from phosphate recovery in wastewater for in-situ immobilization of Cu, Pb and Cd in contaminated soil. J Hazard Mater. 2018;346:273-284 pubmed publisher
    ..Compared with PAL, the lower metal extractability was observed after S-PAL addition. The BCR sequential extraction results showed that both of amendments were beneficial to transform acid soluble fraction to ..
  41. Yeung D, Tang C, Vidovic L, White D, Branford S, Hughes T, et al. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. Blood. 2015;126:2720-3 pubmed publisher
    ..on natural killer (NK) cells have been shown to predict for response in chronic phase-chronic myeloid leukemia (CP-CML) patients treated with tyrosine kinase inhibitors...
  42. Kim Y, Kim D, Lee S, Kim H, Kim Y, Hwang J, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol. 2002;68:272-80 pubmed
    ..MRD) monitoring in 266 post-transplant bone marrow samples from 78 patients with chronic myelogenous leukemia (CML)...
  43. Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, et al. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. Leuk Res. 2016;51:11-18 pubmed publisher
    ..MR, BCR-ABL1 mutations/variants, and BIM polymorphisms were evaluated in a central laboratory...
  44. Xiang J, Zhang Y, Bao D, Cao N, Zhang X, Li P, et al. c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs. Sci Rep. 2017;7:3563 pubmed publisher
    ..Inhibition of c-Abl with imatinib mesylate, an anti-CML drug, or ablation of c-Abl using Prx1-Cre, which marks smooth muscle cells, recapitulated most of the muscularis ..
  45. Sun C, Li Y. [Progress of Study on Cytokines in Myeloproliferative Neoplasms]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:878-82 pubmed publisher
    ..clonal blood disorder, such as polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms(MPN) and are specified by increased production of terminally ..
  46. Halewood C, Traynor A, Bellemans J, Victor J, Amis A. Anteroposterior Laxity After Bicruciate-Retaining Total Knee Arthroplasty Is Closer to the Native Knee Than ACL-Resecting TKA: A Biomechanical Cadaver Study. J Arthroplasty. 2015;30:2315-9 pubmed publisher
    The purpose of this study was to examine whether a bicruciate retaining (BCR) TKA would yield anteroposterior (AP) laxity closer to the native knee than a posterior cruciate ligament retaining (CR) TKA...
  47. Chapin B, Nguyen J, Achim M, Navai N, Williams S, Prokhorova I, et al. Positive margin length and highest Gleason grade of tumor at the margin predict for biochemical recurrence after radical prostatectomy in patients with organ-confined prostate cancer. Prostate Cancer Prostatic Dis. 2018;21:221-227 pubmed publisher
    ..and the highest Gleason grade within the tumor at the PSM could risk stratify patients for biochemical recurrence (BCR)...
  48. Pinelli D, Friedewald J, Haarberg K, Radhakrishnan S, Zitzner J, Hanshew W, et al. Assessing the potential of angiotensin II type 1 receptor and donor specific anti-endothelial cell antibodies to predict long-term kidney graft outcome. Hum Immunol. 2017;78:421-427 pubmed publisher
    ..Overall, 4 patients experienced antibody-mediated rejection (AMR), 31 borderline cellular rejection (BCR), 19 cellular rejection (CR) and 3 mixed AMR and CR within the first 24months...
  49. Zitvogel L, Rusakiewicz S, Routy B, Ayyoub M, Kroemer G. Immunological off-target effects of imatinib. Nat Rev Clin Oncol. 2016;13:431-46 pubmed publisher
    ..that has truly changed the fate of patients with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours by targeting the oncogenic drivers of these diseases, BCR-ABL1 and KIT and/or ..
  50. Jabbour E, Soverini S. Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia. Semin Hematol. 2009;46:S22-6 pubmed
    In patients with chronic myeloid leukemia (CML) resistant to imatinib, resistance is commonly associated with mutations in the BCR-ABL protein...
  51. Song W, Park J, Jeon H, Jeong B, Seo S, Jeon S, et al. Comparison of Oncologic Outcomes and Complications According to Surgical Approach to Radical Prostatectomy: Special Focus on the Perineal Approach. Clin Genitourin Cancer. 2017;15:e645-e652 pubmed publisher
    ..Complications were stratified according to the Clavien classification system. The 5-year biochemical recurrence (BCR)-free survival after RPP was 75.3%, which was higher than for RRP (71.4%; P = .007) and comparable with LRP (76...
  52. Wei Y, To K, Au Yeung S. Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells. J Pharmacol Sci. 2015;129:210-5 pubmed publisher
    ..a multitargeted tyrosine kinase inhibitor, exhibits potent anticancer activity against leukemia harboring the Bcr-Abl oncogene and some solid tumors overexpressing c-kit and PDGFR...
  53. Damaraju V, Weber D, Kuzma M, Cass C, Sawyer M. Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors: IDENTIFICATION OF KEY hENT1 AMINO ACID RESIDUES FOR INTERACTION WITH BCR-ABL KINASE INHIBITORS. J Biol Chem. 2016;291:18809-17 pubmed publisher
    ..Imatinib inhibited hCNT2 with an IC50 value of 2.3 ?m Ponatinib inhibited all five hNTs with the greatest effect seen for hENT1 (IC50 value, 9 ?m)...
  54. Tokalioglu S, Yavuz E, Demir S, Patat S. Zirconium-based highly porous metal-organic framework (MOF-545) as an efficient adsorbent for vortex assisted-solid phase extraction of lead from cereal, beverage and water samples. Food Chem. 2017;237:707-715 pubmed publisher
    ..The method was successfully verified by analyzing two certified reference materials (BCR-482 Lichen and SPS-WW1 Batch 114) and spiked chickpea, bean, wheat, lentil, cherry juice, mineral water, well water ..
  55. Nieborowska Skorska M, Sullivan K, Dasgupta Y, Podszywalow Bartnicka P, Hoser G, Maifrede S, et al. Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest. 2017;127:2392-2406 pubmed publisher
    ..PCR, microarrays, and flow cytometry, or indirectly, by the presence of oncogenes such as BCR-ABL1...
  56. Prakash O, Yunis J. High resolution chromosomes of the t(9;22) positive leukemias. Cancer Genet Cytogenet. 1984;11:361-7 pubmed
    ..bone marrow cells from four patients with chronic myelogenous leukemia (CML), and two each with acute lymphocytic (ALL) and acute nonlymphocytic (ANLL) leukemia were used to define the breakpoints involved in the t(9;22) found in ..
  57. Kaitsiotou H, Keul M, Hardick J, Mühlenberg T, Ketzer J, Ehrt C, et al. Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. J Med Chem. 2017;60:8801-8815 pubmed publisher
    ..KIT is targeted for cancer therapy in gastrointestinal stromal tumors (GISTs) and chronic myelogenous leukemia (CML)...
  58. Skrzypczynska K, Zhu J, Weiss A. Positive Regulation of Lyn Kinase by CD148 Is Required for B Cell Receptor Signaling in B1 but Not B2 B Cells. Immunity. 2016;45:1232-1244 pubmed publisher
    ..the T-cell-independent antigens NP-ficoll and Pneumovax 23 and had impaired selection of the B1 B cell receptor (BCR) repertoire...
  59. Cortes J, Lipton J, Rea D, Digumarti R, Chuah C, Nanda N, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood. 2012;120:2573-80 pubmed
    Chronic myeloid leukemia (CML) patients with the BCR-ABL T315I mutation do not benefit from therapy with currently approved tyrosine kinase inhibitors...
  60. Maese L, Tasian S, Raetz E. How is the Ph-like signature being incorporated into ALL therapy?. Best Pract Res Clin Haematol. 2017;30:222-228 pubmed publisher
    ..profile similar to that observed in Philadelphia chromosome-positive (Ph-positive) ALL, but without an underlying BCR-ABL1 translocation...
  61. Till K, Allen J, Talab F, Lin K, Allsup D, Cawkwell L, et al. Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Sci Rep. 2017;7:16784 pubmed publisher
    ..Studies on somatic hypermutation of the antigen binding region, receptor expression levels and signal capacity have all linked BCR on CLL cells to disease prognosis...
  62. Wang Y, Ding W, Jiang F, Chen Z, Cen J, Qi X, et al. Coexistence of p210BCR-ABL and CBF?-MYH11 fusion genes in myeloid leukemia: A report of 4 cases. Oncol Lett. 2017;14:5171-5178 pubmed publisher
    ..The breakpoint cluster region-ABL proto-oncogene 1 (BCR-ABL) rearrangement leads to a p210 chimeric protein in typical chronic ..
  63. Hattori A, Tsunoda M, Konuma T, Kobayashi M, Nagy T, Glushka J, et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature. 2017;545:500-504 pubmed publisher
    ..amino acids (BCAAs), is aberrantly activated and functionally required for chronic myeloid leukaemia (CML) in humans and in mouse models of CML...
  64. Maru Y, Peters K, Afar D, Shibuya M, Witte O, Smithgall T. Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinases induces association of BCR with GRB-2/SOS. Mol Cell Biol. 1995;15:835-42 pubmed
    The human bcr gene encodes a protein with serine/threonine kinase activity, CDC24/dbl homology, a GAP domain, and an SH2-binding region. However, the precise physiological functions of BCR are unknown...
  65. Yan M, Luo J, Ritchie K, Sakai I, Takeuchi K, Ren R, et al. Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood. 2007;110:305-12 pubmed
    ..of wild-type bone marrow cells results in the rapid development of a chronic myeloid leukemia (CML)-like myeloproliferative disease; in contrast, a significantly increased latency of disease development is observed ..
  66. Makhtar S, Husin A, Baba A, Ankathil R. Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients. J Genet. 2017;96:633-639 pubmed
    ..GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with treatment response among Malaysian chronic myeloid leukaemia (CML) patients who everyday undergo 400 mg of imatinib mesylate (IM) therapy...
  67. Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, et al. Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. Exp Hematol. 2018;57:50-59.e6 pubmed publisher
    Chronic myeloid leukemia (CML) is a stem cell (SC) neoplasm characterized by the BCR/ABL1 oncogene...
  68. Elias M, Baba A, Azlan H, Rosline H, Sim G, Padmini M, et al. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res. 2014;38:454-9 pubmed publisher
    ..tyrosine kinase inhibitor (TKI) has resulted in its use as the frontline therapy for chronic myeloid leukemia (CML) across the world...
  69. Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, et al. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Mol Cancer. 2015;14:132 pubmed publisher
    Chronic Myeloid Leukaemia (CML) is caused by the BCR/ABL1 fusion gene. Both the presence and the levels of BCR/ABL1 expression seem to be critical for CML progression from chronic phase (CP) to blast crisis (BC)...
  70. Ceballos M, García Tenorio R, Estela J, Cerdà V, Ferrer L. An integrated automatic system to evaluate U and Th dynamic lixiviation from solid matrices, and to extract/pre-concentrate leached analytes previous ICP-MS detection. Talanta. 2017;175:507-513 pubmed publisher
    ..solid matrices, by the analysis of a soil reference material (IAEA-375), a certified sediment reference material (BCR- 320R) and a phosphogypsum reference material (MatControl CSN-CIEMAT 2008)...
  71. Erasmus M, Matlawska Wasowska K, Kinjyo I, Mahajan A, Winter S, Xu L, et al. Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia. Sci Signal. 2016;9:ra116 pubmed
    ..In human B cell precursor acute lymphoblastic leukemia (BCP-ALL) cells, we showed that frequent, short-lived, homotypic pre-BCR interactions stimulated survival signals, including ..
  72. Glekas A, Pillarsetty N, Punzalan B, Khan N, Smith Jones P, Larson S. In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib. J Nucl Med. 2011;52:1301-7 pubmed publisher
    ..is known to inhibit the dysregulated proliferation of chronic myeloid leukemia, which is associated with the Bcr-Abl kinase; in gastrointestinal stromal tumors, imatinib is known to act via c-Kit kinase inhibition...
  73. Mian A, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, et al. The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia. 2009;23:1614-21 pubmed publisher
    In Philadelphia chromosome-positive (Ph+) leukemia BCR/ABL induces the leukemic phenotype. Targeted inhibition of BCR/ABL by kinase inhibitors leads to complete remission...
  74. Harrach S, Schmidt Lauber C, Pap T, Pavenstädt H, Schlatter E, Schmidt E, et al. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood Cancer J. 2016;6:e470 pubmed publisher
    Although imatinib is highly effective in the treatment of chronic myeloid leukemia (CML), 25-30% patients do not respond or relapse after initial response...
  75. Lombardi L, Nocita C, Bettazzi E, Fibbi D, Carnevale E. Environmental comparison of alternative treatments for sewage sludge: An Italian case study. Waste Manag. 2017;69:365-376 pubmed publisher
    ..The impact assessment was calculated using the CML-IA baseline method...
  76. Yan X, Yang R, Zhao R, Han J, Jia W, Li D, et al. Transcriptional Regulator PhlH Modulates 2,4-Diacetylphloroglucinol Biosynthesis in Response to the Biosynthetic Intermediate and End Product. Appl Environ Microbiol. 2017;83: pubmed publisher
    ..Although most of the genes in the 2,4-DAPG biosynthetic gene cluster (phl) have been characterized, it is still not clear how the pathway-specific regulator phlH is involved in 2,..
  77. Park K, Woo Y, Kim K, Lee S, Ki C, Kim H, et al. Clinical application of catalytically cleavable fluorescence probe technology for multiplexing quantification of BCR-ABL1 fusion transcripts. Clin Chim Acta. 2014;428:72-6 pubmed
    ..fusion transcripts is critical for therapeutic stratification in patients with chronic myelogenous leukemia (CML)...
  78. Haque A, Alam Q, Alam M, Azhar E, Sait K, Anfinan N, et al. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer. Curr Pharm Des. 2016;22:2947-59 pubmed
    ..stabilization, maturation and activity of its various labile oncogenic client proteins such as p53, ErbB2, Bcr-Abl, Akt, Her-2, Cdk4, Cdk6, Raf-1 and v-Src in altered cells...
  79. Deo P, Keogh J, Price N, Clifton P. Effects of Weight Loss on Advanced Glycation End Products in Subjects with and without Diabetes: A Preliminary Report. Int J Environ Res Public Health. 2017;14: pubmed publisher
    ..of this secondary analysis was to determine whether a major AGE species, N?-carboxymethyllysine (CML), was reduced after weight loss. CML values decreased by 17% after weight loss...